Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. 

5AM Ventures

OrbiMed

Roche Venture Fund

Surveyor Capital

Boxer Capital

Janus Henderson Investors

Logos Capital

Cormorant Asset Management

Enliven Therapeutics

#DYK: Approximately 20% of people with CML switch therapy within the 1st year of treatment and up to 40% switch in the first 5 years of treatment. The majority of treatment switches occur early in the patient’s treatment course due to intolerance or lack and/or loss of molecular response. Join us on April 11th, to learn more about ELVN-001, our candidate for the treatment of CML: https://bit.ly/4cyFSP4

#DYK: Thanks to medical advancements, the number of patients living with #CML has more than doubled since the introduction of BCR-ABL TKIs, however, tolerability, safety, resistance and patient convenience concerns have become more prominent as patients can now expect to live on therapy for decades. Learn more: https://bit.ly/4afJ3cP 

We will be hosting a Virtual company event with KOLs on Thursday, 4/11, to discuss ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in #CML, and how ELVN-001 could fit into the CML landscape. Register here: https://bit.ly/4cyFSP4


#ICYMI: Yesterday we announced a $90M financing. We appreciate the support of our existing and new investors. This capital will help us continue to drive towards our goal of helping people with cancer to not only live longer, but live better. For more information, read the press release here: https://bit.ly/3TqPSkz 

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress. Learn more here: https://bit.ly/3Ve4whJ

Immunovative is a company that develops immunotherapy treatments for various diseases.

Immunovative

Rakuten Medical is a biotechnology company specializing in cancer therapies and immunotherapy.

Rakuten Medical

GeoVax is a biotechnology company that develops vaccines and immunotherapies for various infectious diseases and cancers.

GeoVax

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company focused on developing novel therapies for patients suffering from life-threatening diseases. Their lead product candidate, Allocetra™, is designed to rebalance the patient's immune system and provide a therapeutic benefit in a range of clinical indications. The company's research and development efforts are aimed at improving the outcomes of organ transplant recipients and sepsis patients.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 9:51 PM	862afb86
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 14, 2024 9:51 PM	026d8327
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ENLIVENTHERAPEUTICS

Enlivex Therapeutics Ltd.

Last Close

25.43

21/11 19:12

Market Cap

1.08B

Beta: -

Volume Today

55.23K

Avg: -